You are here

Study Evaluating rhBMP-2/CPM in Closed Distal Radius Fractures

Last updated on December 15, 2017

FOR MORE INFORMATION
Study Location
Kuopio, , 70211 Finland
Contact
1-800-718-1021
Eligibility criteria
Condition
The disease, disorder, syndrome, illness, or injury that is being studied.
Radius Fractures
Sex
Females and Males
Age
Pediatric Trials: 0-17 Years
Adult Trials: 18+ Years
50-80 years
Inclusion criteria
The factors, or reasons, that allow a person to participate in a clinical study.
Show details

- Adults aged 50 to 80 years of age; alert and oriented to person, place, and time.

- Acute, closed distal radius fractures (within 4 cm of the tip of the radial styloid
process), classified according to AO/ASIF as either A2 or A3 (extra-articular) or C1
or C2 (intra-articular) fractures.

- Closed fracture reduction and definitive fracture fixation performed within 7 days
after injury by means of external skeletal and/or percutaneous pin fixation. Note:
fractures that are initially treated by closed reduction and casting, then converted
to external or percutaneous pin fixation for definitive fracture fixation within 7
days after injury are eligible for the study.

Other inclusion applies.

Exclusion criteria
The factors, or reasons, that prevent a person from participating in a clinical study.
Show details

- Other fractures of the ipsilateral upper extremity (except for ulnar styloid
fractures) or the contralateral upper extremity (except for previously healed
fractures without residual functional deficit).

- Fracture fixation by other means (eg, plate and screw fixation).

- Planned treatment for the fracture includes any procedure to promote fracture healing
(eg, open reduction internal fixation, bone grafting, non-invasive modalities such as
ultrasound, electrical stimulation, etc). Note: After 12 weeks have elapsed since
administration of the treatment assignment, unanticipated procedures to promote
fracture healing are permitted as clinically indicated.

Other exclusion applies.

NCT00161629
Pfizer
Completed
Study Evaluating rhBMP-2/CPM in Closed Distal Radius Fractures

NEED INFO?

Questions about a trial? Call or email to reach a Pfizer Clinical Trial Contact Center

Pfizer Clinical Trials Contact Center

1-800-718-1021

[email protected]

call now

Try a new search

Search for Clinical Trials by condition, keyword or trial number. Share your location or enter your zip code, city, or country to find studies near you.

Similar Trials

Fractures
NCT00384358
All Genders
55+
Years
Multiple Sites
Tibial Fractures
NCT00533377
All Genders
17+
Years
Multiple Sites
Fractures
NCT00387686
All Genders
18+
Years
Multiple Sites
Study Evaluating rhBMP-2/CPM in Closed Distal Radius Fractures
A Phase 1 Dose-Escalating, Double-Blind, Placebo-Controlled, Multicenter, Safety and Feasibility Study of Recombinant Human Bone Morphogenetic Protein-2 (rhBMP-2)/Calcium Phosphate Matrix (CPM) as an Adjuvant Therapy for Closed Distal Radius Fractures
To evaluate the safety of rhBMP-2/CPM administered to subjects presenting with closed distal radius fractures. The key safety variables comprising this assessment are: 1) incidence of delayed union; 2) median time to fracture union (assessed by the investigators); 3) incidence of local neurovascular events (those involving the region under study [RUS]); and 4) rate of fracture displacement. The primary objective will be met if these outcomes in the active and placebo treatment groups are at least comparable to those of the SOC control group.
Not Provided
Interventional
Phase 1
Allocation: Randomized
Intervention Model: Single Group Assignment
Masking: Double
Primary Purpose: Treatment
Radius Fractures
Drug: rhBMP-2/CPM
Not Provided
Not Provided


*   Includes publications given by the data provider as well as publications
identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
40
January 2007
Not Provided

Inclusion Criteria:

  • Adults aged 50 to 80 years of age; alert and oriented to person, place, and time.
  • Acute, closed distal radius fractures (within 4 cm of the tip of the radial styloid process), classified according to AO/ASIF as either A2 or A3 (extra-articular) or C1 or C2 (intra-articular) fractures.
  • Closed fracture reduction and definitive fracture fixation performed within 7 days after injury by means of external skeletal and/or percutaneous pin fixation. Note: fractures that are initially treated by closed reduction and casting, then converted to external or percutaneous pin fixation for definitive fracture fixation within 7 days after injury are eligible for the study.

Other inclusion applies.

Exclusion Criteria:

  • Other fractures of the ipsilateral upper extremity (except for ulnar styloid fractures) or the contralateral upper extremity (except for previously healed fractures without residual functional deficit).
  • Fracture fixation by other means (eg, plate and screw fixation).
  • Planned treatment for the fracture includes any procedure to promote fracture healing (eg, open reduction internal fixation, bone grafting, non-invasive modalities such as ultrasound, electrical stimulation, etc). Note: After 12 weeks have elapsed since administration of the treatment assignment, unanticipated procedures to promote fracture healing are permitted as clinically indicated.

Other exclusion applies.

Sexes Eligible for Study: All
50 Years to 80 Years   (Adult, Senior)
No
Contact information is only displayed when the study is recruiting subjects
Finland,   France
 
 
NCT00161629
3100N7-114
Not Provided
Not Provided
Not Provided
Not Provided
Wyeth is now a wholly owned subsidiary of Pfizer
Not Provided
Study Director: Medical Monitor Wyeth is now a wholly owned subsidiary of Pfizer
Principal Investigator: Trial Manager For Finland, [email protected]
Wyeth is now a wholly owned subsidiary of Pfizer
December 2007

ICMJE     Data element required by the

International Committee of Medical Journal Editors
and the
World Health Organization ICTRP

FOR MORE INFORMATION

Contact a representative by phone, email, or visiting thte study website. To get updates and notications about this trail, sign up using the form below.

BY PHONE

Pfizer Clinical Trials Contact Center

1-800-718-1021

BY EMAIL

Contact

[email protected]



Call Now